RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+7.31%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.91B
AUM Growth
+$452M
(+7%)
Cap. Flow
+$148M
Cap. Flow
% of AUM
2.14%
Top 10 Holdings %
Top 10 Hldgs %
46.12%
Holding
78
New
10
Increased
15
Reduced
10
Closed
10
Top Buys
| 1 |
Geron
GERN
|
$200M |
| 2 |
Stryker
SYK
|
$143M |
| 3 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$42.5M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
$16.5M |
| 5 |
BIOA
BioAge Labs, Inc. Common Stock
BIOA
|
$16.4M |
Top Sells
| 1 |
Intuitive Surgical
ISRG
|
$90.1M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$71.8M |
| 3 |
Axsome Therapeutics
AXSM
|
$40M |
| 4 |
Vericel Corp
VCEL
|
$36.8M |
| 5 |
Fulcrum Therapeutics
FULC
|
$36.2M |
Sector Composition
| 1 | Healthcare | 99.89% |
| 2 | Financials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Tarsus Pharmaceuticals
TARS
$2.44B
| $112M | 1.62% |
3,412,486
| – | – |
|
|
27
Ultragenyx Pharmaceutical
RARE
$3.04B
| $109M | 1.58% |
1,968,002
-1,291,925
| -40% | -$71.8M |
|
28
Spyre Therapeutics
SYRE
$1.02B
| $95.8M | 1.39% |
3,258,360
| – | – |
|
|
CRGX
29
DELISTED
CARGO Therapeutics
CRGX
| $75.6M | 1.09% |
4,098,955
+20,833
| +0.5% | +$384K |
|
30
Arvinas
ARVN
$580M
| $68.5M | 0.99% |
2,782,329
-185,568
| -6% | -$4.57M |
|
31
Stoke Therapeutics
STOK
$1.08B
| $57.2M | 0.83% |
4,652,285
+427,447
| +10% | +$5.25M |
|
32
89bio
ETNB
$1.37B
| $54.6M | 0.79% |
7,378,548
| – | – |
|
33
CG Oncology
CGON
$2.19B
| $50.7M | 0.73% |
1,344,074
| – | – |
|
34
Glaukos
GKOS
$5.42B
| $50.3M | 0.73% |
386,291
| – | – |
|
35
UroGen Pharma
URGN
$896M
| $48.1M | 0.7% |
3,787,347
+230,000
| +6% | +$2.92M |
|
36
Neurogene
NGNE
$284M
| $47.6M | 0.69% |
1,135,256
+64,691
| +6% | +$2.71M |
|
|
ORKA
37
Oruka Therapeutics, Inc. Common Stock
ORKA
$578M
| $45.4M | 0.66% |
1,850,648
+1,733,981
| +1,486% | +$42.5M |
|
38
Orchestra BioMed
OBIO
$147M
| $42.2M | 0.61% |
8,206,159
+2,585,519
| +46% | +$13.3M |
|
|
SAGE
39
DELISTED
Sage Therapeutics
SAGE
| $40.4M | 0.58% |
5,591,700
+111,123
| +2% | +$802K |
|
40
Taysha Gene Therapies
TSHA
$791M
| $30M | 0.43% |
14,946,420
-3,853,879
| -20% | -$7.75M |
|
41
Cullinan Oncology
CGEM
$456M
| $28.6M | 0.41% |
1,705,960
+653,330
| +62% | +$10.9M |
|
|
TEM
42
Tempus AI, Inc. Class A Common Stock
TEM
$13.3B
| $22.6M | 0.33% |
400,000
| – | – |
|
43
GH Research
GHRS
$870M
| $22.3M | 0.32% |
3,327,129
| – | – |
|
|
LENZ
44
LENZ Therapeutics
LENZ
$1.12B
| $20.5M | 0.3% |
863,389
| – | – |
|
45
ESSA Pharma
EPIX
$11.2M
| $19.8M | 0.29% |
3,261,496
+962,834
| +42% | +$5.83M |
|
46
Tourmaline Bio
TRML
$645M
| $19.1M | 0.28% |
741,656
| – | – |
|
47
Dianthus Therapeutics
DNTH
$781M
| $18.3M | 0.26% |
666,667
| – | – |
|
48
Roivant Sciences
ROIV
$8.6B
| $16.8M | 0.24% |
1,454,273
| – | – |
|
|
BIOA
49
BioAge Labs, Inc. Common Stock
BIOA
$170M
| $16.4M | 0.24% |
+786,353
| New | +$16.4M |
|
50
Replimune Group
REPL
$460M
| $12.4M | 0.18% |
1,133,787
| – | – |
|